Trinity Biotech (NASDAQ:TRIB) vs. Heska (NASDAQ:HSKA) Critical Contrast

Trinity Biotech (NASDAQ:TRIB) and Heska (NASDAQ:HSKA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Insider & Institutional Ownership

51.2% of Trinity Biotech shares are held by institutional investors. Comparatively, 88.4% of Heska shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 14.0% of Heska shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Trinity Biotech and Heska, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech 0 0 0 0 N/A
Heska 0 4 1 0 2.20

Heska has a consensus target price of $91.00, suggesting a potential upside of 22.69%. Given Heska’s higher probable upside, analysts clearly believe Heska is more favorable than Trinity Biotech.

Risk & Volatility

Trinity Biotech has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Earnings and Valuation

This table compares Trinity Biotech and Heska’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trinity Biotech $97.04 million 0.36 -$22.09 million N/A N/A
Heska $127.45 million 4.54 $5.85 million $1.42 52.23

Heska has higher revenue and earnings than Trinity Biotech.

Profitability

This table compares Trinity Biotech and Heska’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trinity Biotech -23.81% 3.20% 1.02%
Heska 1.93% 6.35% 4.85%

Summary

Heska beats Trinity Biotech on 11 of the 12 factors compared between the two stocks.

About Trinity Biotech

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.